FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus [Yahoo! Finance]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Yahoo! Finance
The company reported a loss of 46 cents per share in the year-ago period. The loss narrowed year over year due to higher collaboration revenues. The company earned collaboration revenues of $3.1 million, which beat the Zacks Consensus Estimate of $1 million. The figure also increased from $1.9 million reported in the year-ago quarter. Revenues were derived from preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen under its collaboration with Ono. R&D expenses increased 1.1% to $34.6 million. G&A expenses increased 9.8% to $20.8 million. Cash, cash equivalents and investments as of Sept. 30, 2024, totaled $330.5 million. Shares of Fate have lost 36.3% year to date compared with the industry's decline of 3.7%. Image Source: Zacks Investment Research Find the latest EPS estimates and surprises on Zacks Earnings Calendar FATE is focused on developing and manufacturing universal, off-the-shelf cell products u
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $38.00 price target on the stock, down previously from $72.00.MarketBeat
- The Galien Foundation Honors 2024 Prix Galien Award RecipientsPR Newswire
- Immunocore to present at upcoming investor conferencesGlobeNewswire
- Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $78.00 to $71.00. They now have a "buy" rating on the stock.MarketBeat
- Immunocore reports third quarter financial results and provides a business updateGlobeNewswire
IMCR
Earnings
- 11/6/24 - Beat
IMCR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMCR's page on the SEC website